CD274 and renal cell carcinoma: 22 of 30 studies investigating the impact of PD-L1 expression on patient prognosis in 36–756 RCC patients have reported significantly worse outcomes in patients with PD-L1 positive tumors [13, 15, 19, 21–32, 39, 40, 49–51, 53].